Cancer
Lung cancer in Chongqing
重庆 肺癌
9 hospitals in Chongqing
Order: papers led on lung cancer, 2021–2025, then A–Z. Research activity, not a rating of care.
Only hospitals listed for lung cancer: those with enough papers or registered trials on it in the records this site uses. Other hospitals in Chongqing may also treat it. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first.
- 111 papers ledNo open trial led
- 77 papers led
- 68 papers led
- 67 papers led
- 61 papers led
- 32 papers ledNo open trial led
- 6 papers ledNo open trial led
- 2 papers led
- 0 papers led
Lung cancer in every city Chongqing on the disease page, with the national map
open trials on lung cancer with a hospital in Chongqing
Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 18 Nov 2026, with a listed hospital in Chongqing as lead sponsor or study site. 10 of them are led by a hospital in Chongqing. Check the registry for the current status. Whether someone can take part is decided by the study team.
Only trials registered on ClinicalTrials.gov are counted. Trials registered only in China’s own registry (ChiCTR) are not.
- RecruitingctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)
- Phase
- Phase 2
- Started
- 2026-03
- Posted
- Registry
- NCT06951646
Age 18 years to 75 years (registered criteria)
Led by Second Xiangya Hospital; 12 listed hospitals as study sitesChangsha, Chongqing, Nanchang, Nanning, Shenyang, Taiyuan, Wuhan, Xinxiang
- RecruitingSymbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2026-01
- Posted
- Registry
- NCT07222566
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 36 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jiangmen, Jinan, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Taiyuan, Taizhou, Wenzhou, Wuhan, Xiangyang, Xinxiang, Yangzhou, Zhengzhou
- RecruitingFirst in Human Study of SIM0610 in Solid Tumors
- Phase
- Phase 1
- Started
- 2026-01
- Posted
- Registry
- NCT07348211
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesChongqing, Harbin, Shanghai, Shenyang
- RecruitingA Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
- Phase
- Phase 3
- Started
- 2026-03
- Posted
- Registry
- NCT07361497
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanchang, Shantou, Shenzhen, Suzhou, Taiyuan, Taizhou, Xi'an, Zhengzhou
- RecruitingRC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)
- Phase
- Phase 3
- Started
- 2026-04
- Posted
- Registry
- NCT07416474
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 66 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Hangzhou, Harbin, Hefei, Jiangmen, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Urumqi, Wenzhou, Wuhan, Xiamen, Xiangyang, Xinxiang, Xuzhou, Yantai, Yinchuan, Zhengzhou, Zhuhai
- RecruitingMK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)
- Phase
- Phase 3
- Started
- 2026-03
- Posted
- Registry
- NCT07431827
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Nanchang, Nanning, Shanghai, Shijiazhuang, Urumqi, Wuhan
- RecruitingBevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases
- Phase
- Phase 3
- Started
- 2026-03
- Posted
- Registry
- NCT07481786
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen University Cancer Center; 2 listed hospitals as study sitesChongqing, Guangzhou
- RecruitingA Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
- Phase
- Phase 3
- Started
- 2026-06
- Posted
- Registry
- NCT07554339
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 26 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Hangzhou, Hefei, Jinan, Nanjing, Nanning, Shanghai, Shijiazhuang, Taiyuan, Taizhou, Urumqi, Wenzhou, Wuhan, Xiamen
- RecruitingA Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation
- Phase
- Phase 3
- Started
- 2026-08
- Posted
- Registry
- NCT07566052
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesChengdu, Chongqing, Guangzhou, Hangzhou, Hohhot, Nanchang, Nanning, Suzhou, Taiyuan
- RecruitingA Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)
- Phase
- Phase 2
- Started
- 2026-07
- Posted
- Registry
- NCT07622186
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Hangzhou, Harbin, Jinan, Kunming, Nanchang, Nanjing, Nanning, Shenyang, Taiyuan, Tianjin, Xi'an, Xiamen, Xiangyang, Zhengzhou
- RecruitingAcupoint Application for Chemotherapy-Induced Nausea and Vomiting in Lung Cancer
- Phase
- N/A
- Started
- 2026-07
- Posted
- Registry
- NCT07768124
Age 18 years to 75 years (registered criteria)
Led by Affiliated Yongchuan Hospital of Chongqing Medical UniversityChongqing
- RecruitingSafety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
- Phase
- Phase 2/Phase 3
- Started
- 2025-01
- Posted
- Registry
- NCT06712316
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chongqing, Hangzhou, Jinan, Shanghai, Shantou, Shijiazhuang, Suzhou, Taizhou, Wuhan, Yangzhou
- RecruitingSafety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
- Phase
- Phase 3
- Started
- 2025-02
- Posted
- Registry
- NCT06712355
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Bengbu, Changchun, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Shanghai, Shantou, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Wenzhou, Wuhan, Xiangyang, Xinxiang, Yangzhou, Zhengzhou
- RecruitingSubstudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)
- Phase
- Phase 2
- Started
- 2025-05
- Posted
- Registry
- NCT06780098
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesBeijing, Chongqing, Fuzhou, Nanjing, Nanning, Shanghai, Zhengzhou
- RecruitingStudy of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2025-04
- Posted
- Registry
- NCT06801834
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Linyi, Nanchang, Nanjing, Shanghai, Shenzhen, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Xinxiang, Yangzhou, Zhengzhou
- RecruitingA Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2025-02
- Posted
- Registry
- NCT06848699
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesChangsha, Chongqing, Jinan
- RecruitingReal World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy
- Phase
- Not given
- Started
- 2025-04
- Posted
- Registry
- NCT06862869
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jiangmen, Jinan, Lanzhou, Nanchang, Nanjing, Nantong, Shanghai, Shenzhen, Shijiazhuang, Taiyuan, Taizhou, Wuhan, Wuxi, Xi'an, Yinchuan, Zhanjiang, Zunyi
- RecruitingA Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- Phase
- Phase 3
- Started
- 2025-04
- Posted
- Registry
- NCT06875310
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 39 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Shantou, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Wuhan, Xiamen, Xinxiang, Yangzhou
- RecruitingStudy of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2025-03
- Posted
- Registry
- NCT06890598
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 32 listed hospitals as study sitesAnyang, Beijing, Changsha, Chengdu, Chongqing, Foshan, Guangzhou, Hangzhou, Harbin, Jinan, Luoyang, Nanning, Shanghai, Shantou, Shenzhen, Suzhou, Taizhou, Tianjin, Wuhan, Xi'an
- RecruitingStudy of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2025-10
- Posted
- Registry
- NCT06899126
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanjing, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Xiangyang, Zhengzhou
- RecruitingA Study on Exploring the Abscopal Effect Induced by Different Radioimmunotherapy Combination Patterns in the Treatment of Non-Small Cell Lung Cancer With Multiple Metastases
- Phase
- Phase 2
- Started
- 2025-07
- Posted
- Registry
- NCT06947694
Age 18 years to 75 years (registered criteria)
Led by Xinqiao Hospital, Army Medical UniversityChongqing
- RecruitingStudy on the Optimal Combination Pattern of the Combined Treatment of Radiotherapy and Immunotherapy for the Abscopal Effect in Non-Small Cell Lung Cancer (NSCLC) With Multiple Metastases
- Phase
- Phase 2
- Started
- 2025-07
- Posted
- Registry
- NCT06953843
Age 18 years to 75 years (registered criteria)
Led by Xinqiao Hospital, Army Medical UniversityChongqing
- RecruitingA Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC
- Phase
- Phase 2
- Started
- 2025-06
- Posted
- Registry
- NCT06962865
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Hangzhou, Harbin, Jinan, Kunming, Linyi, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiangyang, Yantai, Zhengzhou
- RecruitingA Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
- Phase
- Phase 3
- Started
- 2025-06
- Posted
- Registry
- NCT07010263
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chongqing, Fuzhou, Guangzhou, Harbin, Jiangmen, Jinan, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xi'an, Xinxiang, Yinchuan, Zhengzhou, Zunyi
- RecruitingHypofractionated Versus Conventional Chemoradiotherapy Followed by Consolidative Immunotherapy in Locally Advanced NSCLC
- Phase
- Phase 3
- Started
- 2025-07
- Posted
- Registry
- NCT07052669
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer Center; 1 listed hospital as study siteChongqing, Guangzhou
- RecruitingGolidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC
- Phase
- Phase 2
- Started
- 2025-10
- Posted
- Registry
- NCT07110103
Age 18 years to Not stated (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMS; 1 listed hospital as study siteBeijing, Chongqing
- RecruitingA Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
- Phase
- Phase 1/Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07111520
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 22 listed hospitals as study sitesChangchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hefei, Jinan, Nanchang, Qingdao, Shanghai, Shijiazhuang, Suzhou, Tianjin, Wuhan, Xiangyang, Xinxiang, Xuzhou, Yangzhou
- RecruitingA Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases
- Phase
- Not given
- Started
- 2025-12
- Posted
- Registry
- NCT07143045
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesChangchun, Changsha, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou, Harbin, Hefei, Kunming, Nanchang, Nanjing, Nanning, Qingdao, Shenyang, Shenzhen, Taiyuan, Tianjin, Wuhan, Xiamen, Yangzhou, Zhengzhou
- RecruitingA Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- Phase
- Phase 3
- Started
- 2025-09
- Posted
- Registry
- NCT07144280
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Taizhou, Wuhan, Xi'an, Xuzhou, Zhengzhou
- RecruitingStudy to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
- Phase
- Phase 3
- Started
- 2025-12
- Posted
- Registry
- NCT07185997
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Dalian, Foshan, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Hohhot, Jinan, Kunming, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Nantong, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Weifang, Wuhan, Xinxiang, Zhengzhou
- RecruitingA Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
- Phase
- Phase 3
- Started
- 2025-10
- Posted
- Registry
- NCT07190248
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Taiyuan, Taizhou, Wuhan, Xi'an, Xiamen, Zhengzhou
- RecruitingA Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2025-11
- Posted
- Registry
- NCT07217301
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Luzhou, Nanchang, Nanjing, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wenzhou, Xi'an, Xinxiang, Xuzhou, Zhengzhou
- RecruitingFunctional Lung Avoidance Radiotherapy Guided by 4DCT Pulmonary Ventilation Function Imaging: A Prospective Single-arm Clinical Study
- Phase
- N/A
- Started
- 2025-10
- Posted
- Registry
- NCT07339644
Age 18 years to 85 years (registered criteria)
Led by Second Affiliated Hospital of Chongqing Medical UniversityChongqing
- RecruitingTislelizumab Combined With Chemotherapy Followed by Thoracic Consolidation Radiotherapy in the First-line Treatment of Extensive Stage Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2025-10
- Posted
- Registry
- NCT07425795
Age 18 years to 75 years (registered criteria)
Led by Chongqing University Cancer HospitalChongqing
- RecruitingA Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
- Phase
- Phase 2
- Started
- 2024-01
- Posted
- Registry
- NCT05956587
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesChongqing, Fuzhou, Guangzhou, Hangzhou, Linyi, Luoyang, Nanchang, Tianjin, Wuhan, Xi'an, Zhengzhou
- RecruitingPhase II Trial: Low-Dose Radiation + SBRT + Sintilimab + Chemotherapy vs. Sintilimab + Chemotherapy in Locally Advanced or Metastatic Squamous Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2024-03
- Posted
- Registry
- NCT06121505
Age 18 years to 75 years (registered criteria)
Led by West China Hospital; 4 listed hospitals as study sitesChengdu, Chongqing, Nanchong, Wuhan
- RecruitingA Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2024-05
- Posted
- Registry
- NCT06203210
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Hangzhou, Harbin, Jinan, Linyi, Nanchang, Shanghai, Shenyang, Tianjin, Urumqi, Wuhan, Xiangyang, Yantai, Zhengzhou
- RecruitingD-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure
- Phase
- Phase 3
- Started
- 2024-03
- Posted
- Registry
- NCT06300177
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 63 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Haikou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luoyang, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Weifang, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Xinxiang, Xuzhou, Zhanjiang, Zhengzhou, Zunyi
- RecruitingA Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
- Phase
- Phase 3
- Started
- 2024-05
- Posted
- Registry
- NCT06345729
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 36 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanjing, Shanghai, Suzhou, Taiyuan, Taizhou, Urumqi, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Zhengzhou
- RecruitingA Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2024-07
- Posted
- Registry
- NCT06427941
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Nanchang, Nanning, Shijiazhuang, Wenzhou, Wuhan, Xuzhou
- RecruitingA Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
- Phase
- Phase 3
- Started
- 2024-10
- Posted
- Registry
- NCT06561386
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang, Nanning, Shanghai, Shenyang, Taiyuan, Taizhou, Tianjin, Xinxiang
- RecruitingA Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients
- Phase
- Phase 3
- Started
- 2024-11
- Posted
- Registry
- NCT06564324
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Zhengzhou
- RecruitingCarbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor
- Phase
- Phase 1/Phase 2
- Started
- 2024-11
- Posted
- Registry
- NCT07433283
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Haikou, Harbin, Shanghai, Zhengzhou
- RecruitingEfficacy and Safety of Super-hyperfractionation Pulse Radiotherapy Combined With ICIs for Advanced NSCLC
- Phase
- N/A
- Started
- 2023-08
- Posted
- Registry
- NCT05754203
Age 18 years to 75 years (registered criteria)
Led by Xinqiao Hospital, Army Medical UniversityChongqing
- RecruitingA Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Phase
- Phase 3
- Started
- 2023-11
- Posted
- Registry
- NCT05920356
Age 18 years to 100 years (registered criteria)
Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shantou, Shijiazhuang, Taiyuan, Taizhou, Tianjin, Weifang, Wuhan, Xi'an, Xiamen, Xiangyang, Zhengzhou
- RecruitingPhase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
- Phase
- Phase 3
- Started
- 2023-11
- Posted
- Registry
- NCT06095583
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Qingdao, Shanghai, Shenyang, Shenzhen, Taiyuan, Taizhou, Tianjin, Wuhan, Xiamen, Yinchuan, Zhengzhou
- RecruitingRecistTM Criteria in Evaluating the Efficacy of Targeted Therapy for NSCLC
- Phase
- Not given
- Started
- 2023-11
- Posted
- Registry
- NCT06142058
Age 18 years to Not stated (registered criteria)
Led by Dapping HospitalChongqing
- RecruitingA Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Phase
- Phase 3
- Started
- 2022-03
- Posted
- Registry
- NCT04928846
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Hohhot, Jinan, Kunming, Linyi, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Taizhou, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Zhanjiang, Zhengzhou
- RecruitingAn Observational Clinical Study of Stereotactic Radiotherapy for Advanced Non-Small Cell Lung Cancer With Stable Disease After PD-1 Inhibitor Treatment
- Phase
- Not given
- Started
- 2022-08
- Posted
- Registry
- NCT05486650
Age 18 years to 75 years (registered criteria)
Led by Xinqiao Hospital, Army Medical UniversityChongqing
- RecruitingAdjuvant Treatment Based on MRD for EGFR Mutant NSCLC
- Phase
- Phase 2
- Started
- 2022-09
- Posted
- Registry
- NCT05536505
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Chongqing, Foshan, Fuzhou, Guangzhou, Hangzhou, Hefei, Qingdao, Shanghai, Shenzhen, Wuhan, Xiamen, Zhongshan
- RecruitingRinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Phase
- Phase 1/Phase 2
- Started
- 2022-12
- Posted
- Registry
- NCT05579366
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan
- RecruitingStudy of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2021-09
- Posted
- Registry
- NCT04930432
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 56 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Nanchang, Nanjing, Nanning, Nantong, Qingdao, Shanghai, Shantou, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Weifang, Wenzhou, Wuhan, Xi'an, Xiamen, Xuzhou, Yantai, Zhengzhou
- RecruitingPhase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- Phase
- Phase 2/Phase 3
- Started
- 2020-12
- Posted
- Registry
- NCT04613596
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 30 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanning, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Taiyuan, Taizhou, Wuhan, Xi'an, Xiamen, Zhengzhou
- Not yet recruitingA Study to Learn the Safety and Efficacy of HLX37 in Combination With Chemotherapy for First-line Treatment in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Phase
- Phase 2/Phase 3
- Started
- 2026-11
- Posted
- Registry
- NCT07865910
Age 18 days to 75 days (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesAnyang, Beijing, Chongqing, Guangzhou, Jinan, Nanning, Qingdao, Shijiazhuang, Wuhan, Xuzhou, Zhengzhou, Zunyi
- Not yet recruitingEnteral Nutrition With L-Carnitine for Cachexia in Non-Small Cell Lung Cancer
- Phase
- N/A
- Started
- 2025-06
- Posted
- Registry
- NCT07035444
Age 18 years to Not stated (registered criteria)
Led by Daping Hospital, Army Medical UniversityChongqing
- Not yet recruitingPostbiotics Ameliorate Cachexia in Patients With Non-small-cell Lung Cancer
- Phase
- N/A
- Started
- 2025-11
- Posted
- Registry
- NCT07185308
Age 18 years to Not stated (registered criteria)
Led by Daping Hospital, Army Medical UniversityChongqing
- Not yet recruitingYK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
- Phase
- Phase 3
- Started
- 2023-05
- Posted
- Registry
- NCT05767892
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Hohhot, Jinan, Kunming, Luoyang, Nanchang, Nanjing, Qingdao, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Wuhan, Xi'an, Xiamen, Zhengzhou
- Not yet recruitingA Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2023-11
- Posted
- Registry
- NCT05990127
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Luoyang, Nanchang, Qingdao, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xinxiang, Xuzhou, Yinchuan, Zhengzhou
- Enrolling by invitationEfficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection
- Phase
- Phase 3
- Started
- 2021-08
- Posted
- Registry
- NCT04762459
Age 18 years to 130 years (registered criteria)
Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Kunming, Nanchang, Nanjing, Ningbo, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Weifang, Wenzhou, Wuhan, Xi'an, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
Disease research in Chongqing
Each number is papers led on that disease, 2021–2025. “Open” counts open trials the hospital leads. Hospitals A–Z; this is not a ranking.
A blank cell means no papers or trials were found in these records. It does not mean the hospital does not treat that disease.
| Cancer | Blood disorders | Other diseases | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospital | Nasopharyngeal carcinoma | Oesophageal squamous cell carcinoma | Hepatocellular carcinoma | Stomach cancer | Lung cancer | Pancreatic cancer | Breast cancer | Glioma | Hepatoblastoma | Retinoblastoma | Chordoma | Osteosarcoma | Gastrointestinal stromal tumour | Neuroblastoma | Ewing sarcoma | Multiple myeloma | B-cell acute lymphoblastic leukaemia | Aplastic anaemia | Haemophagocytic lymphohistiocytosis | Lymphoma | Beta thalassaemia | Haemophilia A | Atypical haemolytic uraemic syndrome | Thrombotic thrombocytopenic purpura | Fanconi anaemia | Neuromyelitis optica spectrum disorder | IgG4-related disease | Myasthenia gravis | Moyamoya disease | Wilson disease | Biliary atresia | Coronary heart disease | Congenital heart disease | Scoliosis | Anti-NMDA receptor encephalitis | Takayasu arteritis | Hepatic echinococcosis | Idiopathic pulmonary fibrosis | Lymphangioleiomyomatosis | Amyotrophic lateral sclerosis | Spinal muscular atrophy | Fabry disease | Pompe disease | Duchenne muscular dystrophy | Behçet disease | Alport syndrome | IgA nephropathy | Gaucher disease | Niemann–Pick disease type C | Osteogenesis imperfecta | Primary biliary cholangitis | Primary sclerosing cholangitis | Congenital diaphragmatic hernia | Hirschsprung disease | Inherited epidermolysis bullosa | Hereditary angioedema | Familial adenomatous polyposis | Leber hereditary optic neuropathy | Majeed syndrome | NGLY1 deficiency | ISG15 deficiency | Shortlist |
| Affiliated Hospital of Chongqing Three Gorges Medical College重庆三峡医药高等专科学校附属人民医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Affiliated Yongchuan Hospital of Chongqing Medical University重庆医科大学附属永川医院 | none | none | none | none | 21 open | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Bishan Hospital, Chongqing Medical University重庆市璧山区人民医院 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Changqing Traditional Chinese Medicine Hospital永川长青中医医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Children's Hospital of Chongqing Medical University重庆医科大学附属儿童医院 | none | none | none | none | none | none | none | 19 | 4 | 1 | none | 6 | none | 49 | 1 | none | 1 | 0 | 7 | 9 | 1 | 0 | none | none | none | none | none | none | none | none | 6 | 14 | 36 | 2 | 10 | 0 | none | 1 | none | 1 | 1 | 0 | 0 | 5 | 1 | none | 3 | none | none | none | 1 | none | 4 | 8 | 1 | none | 1 | 0 | none | none | 1 | |
| Chongqing Aier Eye Hospital重庆爱尔眼科医院 | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Chongqing Bright Eye Hospital重庆普瑞眼科医院 | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Chongqing General Hospital重庆大学附属中心医院(重庆市人民医院) | 3 | none | none | none | none | 12 | 7 | 13 | none | none | none | 3 | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Chongqing Hospital重庆市中医院 | none | none | none | none | none | none | none | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | 1 | 0 | none | none | 0 | none | none | none | 0 | none | none | none | none | none | none | |
| Chongqing Liangping District People's Hospital重庆市梁平区人民医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Chongqing Maternal and Child Health Hospital重庆市妇幼保健院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Chongqing University Cancer Hospital重庆大学附属肿瘤医院 | 141 open | 4 | 23 | 15 | 771 open | 7 | 70 | 10 | none | 1 | none | 1 | 0 | 1 | none | 2 | none | none | none | 22 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | |
| Chongqing University Central Hospital重庆市急救医疗中心 | none | none | none | none | none | none | none | none | none | none | none | 1 | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Chongqing University Fuling Hospital重庆市涪陵中心医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Chongqing University Three Gorges Hospital重庆大学附属三峡医院 | none | 11 open | none | none | 6 | none | none | none | none | none | none | 1 | none | 1 | none | 3 | none | none | none | none | 0 | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | |
| Chongqing Wanzhou District Traditional Chinese Hospital重庆三峡医药高等专科学校附属中医院 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Chongqing Yubei District People's Hospital重庆市渝北区人民医院 | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Daping Hospital, Army Medical University陆军军医大学大坪医院 | 2 | 82 open | none | 93 open | 682 open | none | 161 open | 141 open | none | 1 | none | 5 | 0 | 0 | none | none | none | none | 2 | 51 open | none | none | none | 1 | none | none | none | none | none | none | none | 9 | 2 | none | none | none | none | 1 | none | 3 | none | 1 | none | none | 0 | none | 1 | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | |
| Dapping Hospital | none | none | none | none | 01 open | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Dianjiang People's Hospital重庆市垫江县人民医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| First Affiliated Hospital of Chongqing Medical University重庆医科大学附属第一医院 | 8 | 7 | 641 open | 35 | 111 | 32 | 114 | 16 | none | none | none | 25 | 121 open | 1 | 2 | 4 | none | 1 | none | 21 | 1 | none | none | none | none | 8 | 2 | 10 | none | none | none | 24 | 8 | none | 1 | none | none | 3 | none | 5 | none | none | none | 1 | 28 | none | 1 | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | |
| Fuling Central Hospital重庆市涪陵中心医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Jiangjin Center Hospital重庆大学附属江津医院(重庆市江津区中心医院) | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Second Affiliated Hospital of Chongqing Medical University重庆医科大学附属第二医院 | none | 10 | 108 | 23 | 671 open | 23 | 43 | 18 | none | 5 | none | 7 | 4 | 2 | 1 | none | none | 2 | 2 | none | none | 1 | none | 2 | 1 | none | none | none | none | none | none | 10 | 4 | none | none | 1 | 1 | 1 | none | 1 | none | none | none | none | 1 | none | 1 | none | 1 | none | 0 | none | none | none | none | none | none | none | none | none | none | |
| Shapingba Hospital, Chongqing University重庆市沙坪坝区人民医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Southwest Hospital, Army Medical University陆军军医大学第一附属医院(西南医院) | 3 | 0 | 57 | 242 open | 32 | 14 | 47 | 40 | none | none | none | 7 | 1 | 0 | none | 0 | none | 2 | 2 | 5 | none | none | 0 | none | 1 | none | none | none | 2 | none | none | 7 | 3 | 4 | none | none | none | none | none | 1 | none | none | none | 0 | 1 | none | 1 | none | none | none | 5 | 1 | none | none | 0 | none | none | none | none | none | none | |
| Third Affiliated Hospital of Chongqing Medical University重庆医科大学附属第三医院(方大医院) | none | 3 | none | none | none | none | none | none | none | none | none | 2 | 1 | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Third Affiliated Hospital, Army Medical University中国人民解放军陆军特色医学中心 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| University-Town Hospital, Chongqing Medical University重庆医科大学附属大学城医院 | none | none | none | none | none | none | none | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Wushan County People's Hospital重庆市巫山县人民医院 | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Xinqiao Hospital, Army Medical University陆军军医大学第二附属医院(新桥医院) | 31 open | none | 23 | 18 | 614 open | 7 | none | 14 | 0 | none | none | 5 | 0 | none | none | 5 | 3 | none | none | 14 | none | 0 | none | 0 | none | none | none | none | none | none | none | 8 | 4 | 2 | none | none | none | none | none | none | none | none | none | none | none | 2 | 4 | none | none | none | none | none | 2 | none | none | none | none | none | none | none | none | |
| Yongchuan Hospital重庆医科大学附属永川医院 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 4 | none | none | 0 | none | none | none | none | none | none | none | none | 0 | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
Column labels are short names. Choose one to open that disease in Chongqing.
- Glioma 19
- Hepatoblastoma 4
- Retinoblastoma 1
- Osteosarcoma 6
- Neuroblastoma 49
- Ewing sarcoma 1
- B-cell acute lymphoblastic leukaemia 1
- Aplastic anaemia 0
- Haemophagocytic lymphohistiocytosis 7
- Lymphoma 9
- Beta thalassaemia 1
- Haemophilia A 0
- Biliary atresia 6
- Coronary heart disease 14
- Congenital heart disease 36
- Scoliosis 2
- Anti-NMDA receptor encephalitis 10
- Takayasu arteritis 0
- Idiopathic pulmonary fibrosis 1
- Amyotrophic lateral sclerosis 1
- Spinal muscular atrophy 1
- Fabry disease 0
- Pompe disease 0
- Duchenne muscular dystrophy 5
- Behçet disease 1
- IgA nephropathy 3
- Primary biliary cholangitis 1
- Congenital diaphragmatic hernia 4
- Hirschsprung disease 8
- Inherited epidermolysis bullosa 1
- Familial adenomatous polyposis 1
- Leber hereditary optic neuropathy 0
- ISG15 deficiency 1
- Nasopharyngeal carcinoma 141 open
- Oesophageal squamous cell carcinoma 4
- Hepatocellular carcinoma 23
- Stomach cancer 15
- Lung cancer 771 open
- Pancreatic cancer 7
- Breast cancer 70
- Glioma 10
- Retinoblastoma 1
- Osteosarcoma 1
- Gastrointestinal stromal tumour 0
- Neuroblastoma 1
- Multiple myeloma 2
- Lymphoma 22
- Amyotrophic lateral sclerosis 2
- Familial adenomatous polyposis 0
- Nasopharyngeal carcinoma 2
- Oesophageal squamous cell carcinoma 82 open
- Stomach cancer 93 open
- Lung cancer 682 open
- Breast cancer 161 open
- Glioma 141 open
- Retinoblastoma 1
- Osteosarcoma 5
- Gastrointestinal stromal tumour 0
- Neuroblastoma 0
- Haemophagocytic lymphohistiocytosis 2
- Lymphoma 51 open
- Thrombotic thrombocytopenic purpura 1
- Coronary heart disease 9
- Congenital heart disease 2
- Idiopathic pulmonary fibrosis 1
- Amyotrophic lateral sclerosis 3
- Fabry disease 1
- Behçet disease 0
- IgA nephropathy 1
- Hirschsprung disease 0
- Nasopharyngeal carcinoma 8
- Oesophageal squamous cell carcinoma 7
- Hepatocellular carcinoma 641 open
- Stomach cancer 35
- Lung cancer 111
- Pancreatic cancer 32
- Breast cancer 114
- Glioma 16
- Osteosarcoma 25
- Gastrointestinal stromal tumour 121 open
- Neuroblastoma 1
- Ewing sarcoma 2
- Multiple myeloma 4
- Aplastic anaemia 1
- Lymphoma 21
- Beta thalassaemia 1
- Neuromyelitis optica spectrum disorder 8
- IgG4-related disease 2
- Myasthenia gravis 10
- Coronary heart disease 24
- Congenital heart disease 8
- Anti-NMDA receptor encephalitis 1
- Idiopathic pulmonary fibrosis 3
- Amyotrophic lateral sclerosis 5
- Duchenne muscular dystrophy 1
- Behçet disease 28
- IgA nephropathy 1
- Inherited epidermolysis bullosa 1
- Oesophageal squamous cell carcinoma 10
- Hepatocellular carcinoma 108
- Stomach cancer 23
- Lung cancer 671 open
- Pancreatic cancer 23
- Breast cancer 43
- Glioma 18
- Retinoblastoma 5
- Osteosarcoma 7
- Gastrointestinal stromal tumour 4
- Neuroblastoma 2
- Ewing sarcoma 1
- Aplastic anaemia 2
- Haemophagocytic lymphohistiocytosis 2
- Haemophilia A 1
- Thrombotic thrombocytopenic purpura 2
- Fanconi anaemia 1
- Coronary heart disease 10
- Congenital heart disease 4
- Takayasu arteritis 1
- Hepatic echinococcosis 1
- Idiopathic pulmonary fibrosis 1
- Amyotrophic lateral sclerosis 1
- Behçet disease 1
- IgA nephropathy 1
- Niemann–Pick disease type C 1
- Primary biliary cholangitis 0
- Nasopharyngeal carcinoma 3
- Oesophageal squamous cell carcinoma 0
- Hepatocellular carcinoma 57
- Stomach cancer 242 open
- Lung cancer 32
- Pancreatic cancer 14
- Breast cancer 47
- Glioma 40
- Osteosarcoma 7
- Gastrointestinal stromal tumour 1
- Neuroblastoma 0
- Multiple myeloma 0
- Aplastic anaemia 2
- Haemophagocytic lymphohistiocytosis 2
- Lymphoma 5
- Atypical haemolytic uraemic syndrome 0
- Fanconi anaemia 1
- Moyamoya disease 2
- Coronary heart disease 7
- Congenital heart disease 3
- Scoliosis 4
- Amyotrophic lateral sclerosis 1
- Duchenne muscular dystrophy 0
- Behçet disease 1
- IgA nephropathy 1
- Primary biliary cholangitis 5
- Primary sclerosing cholangitis 1
- Inherited epidermolysis bullosa 0
- Nasopharyngeal carcinoma 31 open
- Hepatocellular carcinoma 23
- Stomach cancer 18
- Lung cancer 614 open
- Pancreatic cancer 7
- Glioma 14
- Hepatoblastoma 0
- Osteosarcoma 5
- Gastrointestinal stromal tumour 0
- Multiple myeloma 5
- B-cell acute lymphoblastic leukaemia 3
- Lymphoma 14
- Haemophilia A 0
- Thrombotic thrombocytopenic purpura 0
- Coronary heart disease 8
- Congenital heart disease 4
- Scoliosis 2
- Alport syndrome 2
- IgA nephropathy 4
- Congenital diaphragmatic hernia 2
Other cities nearby
Straight-line distance from the city centre; counts are hospitals listed for lung cancer.
Counts are listed hospitals only, not every hospital in each city.
Where these numbers come from
Papers
English-language PubMed papers, 2021–2025, where the first or last author lists the hospital first. Definitions
Trials
ClinicalTrials.gov records with the hospital as lead sponsor or site, as of 8 Nov 2026. Search Chongqing on ClinicalTrials.gov
Locations
Locations are shown at city centres. Check the hospital’s website for its address.